Amazentis SA

Amazentis SA is a life science company that employs today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition and pharma applications. The Company’s proprietary lead product candidate, AMAZ-02, an oral formulation of urolithin A, is currently advancing in two pivotal, Phase 2 clinical trials. Amazentis has established an extensive intellectual property portfolio and proprietary know how around urolithin A,
enabling the manufacture and development of advanced products for human applications.